Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02300532

Enrollment

561

Registered

2014-11-25

Start date

2013-01-10

Completion date

2015-03-24

Last updated

2017-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Glioma

Keywords

Malignant Glioma, Glioblastoma Multiforme

Brief summary

Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.

Interventions

OTHERNo intervention

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All-patient of Gliadel implantation

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame
Number of Adverse Events/Serious Adverse Events	Up to 3 months

Secondary

Measure	Time frame	Description
Survival rate	Up to 1 year	Survival rate of subjects measured up to 1 year after implantation of Gliadel

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026